View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
Sponsored by EuroEspes Biotechnology

AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s

Free White Paper

AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s

By EuroEspes Biotechnology

AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s

By EuroEspes Biotechnology
Enter your details to receive the free paper:

AtreMorine is a novel biopharmaceutical compound obtained by means of nondenaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.

E-PodoFavalin-15999 extract is the structural base of AtreMorine and a natural source of L-DOPA, with an average concentration of 25 mg per gram of AtreMorine; it also contains a plethora of other bioactive substances as vegetal proteins, unsaturated fatty acids, minerals and vitamins, vegetal fibre, starch, vegetal pigments (carotenes) and vegetal sterols (phytosterols).

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena